FACTORS ASSOCIATED WITH EARLY OUTCOMES OF MULTIPLE MYELOMA; A 10-YEAR RETROSPECTIVE STUDY IN CHIANGRAI PRACHANUKROH HOSPITAL
Article Sidebar
Main Article Content
Abstract
Background: Multiple myeloma has been announced for approximately 10% of hematologic malignancies. The survival of multiple myeloma in a recent study was 5.2 years. There is no previous study on factors associated with early mortality of multiple myeloma treatment in Chiangrai.
OBJECTIVE: To study factors associated with the early outcomes of multiple myeloma patients.
Methods: A retrospective cohort study was performed to study factors associated with early outcomes in patients aged more than 18 years who were diagnosed with multiple myeloma, according to ICD-10 from 1st January 2010 to 31st December 2020 in Chiangrai Prachanukroh hospital.
Results: 212 patients were included in this study, and 72 (33.96%) passed away within 12 months of diagnosis. The multivariable logistic regression analysis revealed that renal impairment increased the risk of mortality while receiving chemotherapy has proved statistically significant increased survival. The leading causes of death were septicemia, pneumonia and acute kidney injury.
Conclusions and recommendations: Renal failure associated with increased death and chemotherapy was shown statistically significant increased survival in multiple myeloma. There is a need to encourage chemotherapy treatment in these patients. The majority of the early cause of death were infections and acute kidney injury, therefore infectious control and treatment of acute renal failure should be concerned in the early phase of myeloma treatment.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Rajkumar SV. Updated Diagnostic Criteria and Staging System for Multiple Myeloma. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting. 2016;35:e418-23.
Firth J. Haematology: multiple myeloma. Clinical medicine (London, England). 2019;19(1):58-60.
Jones A, Bowcock S, Rachet B. Survival trends in elderly myeloma patients. Eur J Haematol. 2021;106(1):126-31.
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122-8.
Guidelines for diagnosis and treatment of hematologic diseases 2018 vol. 3. Nawarawong W, Numbenchapol T, Wiangnon S, editors. Bangkok: The Thai Society of Hematology; 2018.
Kumar V, Ailawadhi M, Dutta N, Abdulazeez M, Aggarwal CS, Quintero G, et al. Trends in Early Mortality From Multiple Myeloma: A Population-Based Analysis. Clin Lymphoma Myeloma Leuk.
;21(5):e449-e55.
Gregersen H, Vangsted AJ, Abildgaard N, Andersen NF, Pedersen RS, Frølund UC, et al. The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study. Cancer Med. 2017;6(7):1807-16.
Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
Hemasphere. 2021;5(2):e528.
Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013;31(26):3279-87.
Sneyd MJ, Cox B, Morison IM. Trends in myeloma incidence, mortality and survival in New Zealand (1985-2016). Cancer Epidemiol. 2019;60:55-9.
Liu J, Liu W, Mi L, Zeng X, Cai C, Ma J, et al. Incidence and mortality of multiple myeloma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019;12(1):136.
Mohty M, Cavo M, Fink L, Gonzalez-McQuire S, Leleu H, Mateos MV, et al. Understanding mortality in multiple myeloma: Findings of a European retrospective chart review. Eur J Haematol.
;103(2):107-15.
Hsu P, Lin TW, Gau JP, Yu YB, Hsiao LT, Tzeng CH, et al. Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma. Medicine (Baltimore). 2015;94(50):e2305.
